Kite first telegraphed its plans to tackle viral vector production solo in 2019. The company at the time declined to name its investment in the site or how many employees it aimed to recruit.

Contacts Sung Lee, Investors (650) 524-7792 Shant Salakian, Media (424) 384-1841 ...

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) ...